Doc guide reports: February 18, 2008 -- Patients with fibromyalgia syndrome appear to obtain better pain control with the selective serotonin and norepinephrine reuptake inhibitor duloxetine.
Researchers led by Madelaine Wohlreich, MD, Medical Advisor, Eli Lilly and Company, Indianapolis, Indiana, United States, attempted to determine whether treatment with duloxetine 120 mg daily for 3 months could reduce pain severity in patients with fibromyalgia syndrome.
"Duloxetine 60 mg daily and 120 mg daily were superior to placebo during the 3-month treatment period on the coprimary measures, both in brief pain inventory average pain score and the patient's global impressions of improvement," Dr. Wohlreich said in her poster presentation February 14 here at the American Academy of Pain Medicine (AAPM) 24th Annual Meeting.
No comments:
Post a Comment